Latest Regulatory Approval News

Talga Group and SQM have mutually terminated their joint venture for the Aero Project in Sweden due to regulatory delays, with Talga now exploring new partnership opportunities to advance the critical minerals project.

Santana Minerals has taken a major step forward by acquiring freehold ownership of critical lands and extinguishing royalties at its Bendigo-Ophir Gold Project, enhancing project economics amid a strong gold market.

Firebrick Pharma has secured a $102,000 investment from its Philippines strategic partner, Pharma Nutria N.A., Inc., reinforcing its position ahead of the Nasodine nasal spray launch in 2026.

Anteris Technologies has secured its first European regulatory clearance to commence the global PARADIGM Trial for its DurAVR Transcatheter Heart Valve, marking a significant step toward worldwide commercialization.

Clarity Pharmaceuticals has inked a pivotal supply agreement with Nusano to ensure a steady source of copper-67, a critical isotope for its upcoming Phase III prostate cancer trial and future commercialisation plans.

Moho Resources has reported new high-grade gold assays up to 6.98g/t at its Bush Chook Project in Western Australia, extending a mineralised trend to 300 metres and setting the stage for a maiden drill program later this year or early next.

EMVision Medical Devices’ latest Share Purchase Plan has attracted applications exceeding its initial $1 million target, with limited oversubscription capacity remaining ahead of the October 23 closing date.

Provaris Energy has launched a Robotics Innovation Centre in Norway, marking a pivotal step in fabricating and testing advanced hydrogen and liquid CO2 storage tanks. The initiative aims to accelerate prototype completion and commercial scalability by early 2026.

Blue Star Helium Limited is advancing its Galactica helium project in Colorado, aiming for initial commercial production by December 2025, supported by a recent A$4.5 million equity raise.

Entertainment Rewards’ majority shareholder Suzerain Investments has announced a $0.022 per share cash takeover offer, valuing the company at nearly $29 million and offering shareholders a substantial premium.

EVE Health Group Limited has launched a $1.1 million capital raising via a placement to fund the commercial rollout of its two pharmaceutical products, Dyspro and Libbo. The offer includes shares and options, with some subject to shareholder approval.

VHM Limited has secured a significant offtake framework with Mitsui and a US$200 million financing interest from the US Export-Import Bank for its Goschen Rare Earths and Mineral Sands Project, alongside key environmental approvals. These milestones set the stage for a Final Investment Decision in the first half of 2026.